Please use this identifier to cite or link to this item:
|Title:||A multicenter, open-label, noncomparative screening study of Enzastaurin in adult patients with Non-Hodgkin Lymphomas||Authors:||Forsyth, Cecily J ;Gomez-Almaguer, D.;Camargo, J.F.C.;Eliadis, P.E.;Crespo-Solis, E.;Pereira, J.;Gutierrez-Aguirre, C.H.;Rivaz-Vera, S.;Roberson, S.;Lin, B.;Smith, N.V.;Hamid, O.||Issue Date:||Aug-2013||Source:||Volume 13, Issue 4, pp. 398 - 403||Journal title:||Clinical Lymphoma, Myeloma & Leukemia||Abstract:||PURPOSE: To assess the antitumor activity of enzastaurin in patients with non-Hodgkin lymphomas: T-cell lymphoma (n = 23): cutaneous and peripheral T-cell lymphoma; indolent B-cell lymphomas (n = 19): small lymphocytic, follicular grade 1 or 2, marginal zone lymphomas; and aggressive B-cell lymphomas (n = 15): follicular lymphomas grade 3, aggressive lymphoma with a clinical history. The primary objective was to determine overall tumor response. Secondary objectives included duration of response and safety. MATERIALS AND METHODS: In this multicenter, open-label, noncomparative, screening study conducted between December 2007 and February 2009, patients (>/= 18 years) who relapsed after >/= 1 prior systemic treatment or who were intolerant to standard systemic therapy received 250 mg oral enzastaurin (125 mg tablets twice a day; a 1125-mg loading dose on day 1), in 28-day cycles for up to 2 years unless unacceptable toxicity or progressive disease occurred. RESULTS: Responses were seen in follicular lymphomas grade 3 (1/5, 20.0%), cutaneous T-cell lymphoma (2/11, 18.2%), small lymphocytic lymphomas (1/7, 14.3%), and aggressive lymphoma with a clinical history (1/10, 10.0%) in this heavily pretreated patient population (median prior therapies range from 4 to 10). Most drug-related toxicities were grade 1/2, the most common being diarrhea, peripheral edema, and pruritus. CONCLUSIONS: Enzastaurin was well tolerated but demonstrated modest responses across subgroups in this heavily pretreated patient population.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/190||DOI:||10.1016/j.clml.2013.03.005||Pubmed:||http://www.ncbi.nlm.nih.gov/pubmed/ 23770158||ISSN:||2152-2669||Publicaton type:||Journal Article||Keywords:||Cancer
|Study or Trial:||Multicentre Studies|
|Appears in Collections:||Haematology|
Show full item record
checked on Jan 27, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.